HTG Molecular Diagnostics Reports Second Quarter 2022 ResultsCall scheduled for today, August 11, 2022, at 4:30 pm ET

2022-08-11

合作财报

TUCSON, Ariz., Aug. 11, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported recent business highlights and financial results for the quarter ended June 30, 2022. Throughout the quarter ended June 30, 2022, the Company's technology and strategic development efforts were highlighted in a number of customer and KOL presentations and publications including, but not limited to, the following: A webinar titled “Integration of the HTG Transcriptome Panel into Preclinical and Clinical Programs to Drive Precision Medicine Research” featuring Pete Ansell, Ph.D., Scientific Director and Research Fellow, Precision Medicine Oncology at AbbVie, addressed how Dr. Ansell and his team at AbbVie have overcome many challenges they have previously faced using FFPE clinical samples by integrating the HTG Transcriptome Panel (HTP) into their biomarker strategies. In a keynote presentation at the 7th Annual Markets and Markets Biomarker and Companion Diagnostics Conference in San Diego, CA, titled “Implementing Biomarker Strategy in Clinical Trials,” Chetan Deshpande, Director, Biomarker Clinical Assay Lead, Global Product Development at Pfizer discussed the challenges that are generally faced in clinical trials and how Pfizer has leveraged HTG’s proprietary gene expression profiling HTG EdgeSeq technology in multiple clinical trials to overcome these challenges. The first peer-reviewed journal article featuring our HTP was published by one of the participants in our Early Adopter Program in Frontiers in Medicine less than one year after the commercial release of the product. The Company published a second white paper, further establishing the utility of its transcriptome-informed approach to drug design and discovery utilizing its proprietary HTG EdgeSeq technology. A webinar addressing "Drug Candidate Attrition - How to Improve Clinical Development Success and Patent Outcomes," including a presentation from key opinion leader, Dr. Robert Spitale, PhD, University of California - Irvine, further outlined the potential uses of RNA-based platform technologies in drug discovery. In July 2022, the Company entered into an amendment to its June 24, 2020 Loan and Security Agreement (“LSA”) with its lender, Silicon Valley Bank. Under the terms of the amendment, Silicon Valley Bank agreed to waive the existing financial covenant through the remaining term of the LSA in exchange for a partial prepayment of outstanding principal. The remaining principal will continue to amortize through December 2023, the original maturity date of the term loan. Second Quarter 2022 Financial Highlights: Revenue for the quarter ended June 30, 2022 was $1.5 million, compared with $2.1 million for the same period in 2021, and was comprised entirely of product and product-related services revenue. Sales of the HTP to new and existing customers as consumables and sample processing services represented over 42% of revenue for the quarter ended June 30, 2022. Net loss from operations for the quarter ended June 30, 2022 was $5.7 million, compared with $4.1 million for the same period in 2021. Net loss per share was $(0.54) for the quarter ended June 30, 2022 compared with $(0.39) for the second quarter of 2021. Cash, cash equivalents and short-term available-for-sale securities totaled $14.1 million as of June 30, 2022, with current liabilities of approximately $10.2 million and non-current liabilities of $6.5 million. Conference Call and Webcast: HTG will host a conference call for the investment community today beginning at 4:30 p.m. Eastern Time. Conference call and webcast details are as follows: Date: Thursday, August 11, 2022 Time: 4:30 p.m. Eastern Time Toll Free: (800) 954-0602 International: (212) 231-2936 Conference ID: 22019810 Webcast: About HTG: HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, novel therapeutics and clinical diagnostics across a variety of disease areas. Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit . HTG Investor Contact: Ashley Robinson LifeSci Advisors Phone: (617) 430-7577 Email: arr@lifesciadvisors.com -Financial tables follow- HTG Molecular Diagnostics, Inc. Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Product and product-related services revenue $ 1,491,582 $ 2,074,204 $ 2,676,036 $ 3,509,350 Operating expenses: Cost of product and product-related services revenue 1,014,469 971,043 1,869,517 1,756,243 Selling, general and administrative 4,306,916 3,903,815 8,969,927 7,763,434 Research and development 1,847,101 1,281,361 3,767,531 2,653,401 Total operating expenses 7,168,486 6,156,219 14,606,975 12,173,078 Operating loss (5,676,904 ) (4,082,015 ) (11,930,939 ) (8,663,728 ) Other income (expense) (206,425 ) (252,469 ) (449,523 ) (516,614 ) Gain on forgiveness of PPP Loan — 1,735,792 — 1,735,792 Net loss before income taxes (5,883,329 ) (2,598,692 ) (12,380,462 ) (7,444,550 ) Provision for income taxes (4,880 ) (16,260 ) (5,266 ) (18,709 ) Net loss $ (5,888,209 ) $ (2,614,952 ) $ (12,385,728 ) $ (7,463,259 ) Net loss per share, basic and diluted $ (0.54 ) $ (0.39 ) $ (1.30 ) $ (1.17 ) Shares used in computing net loss per share, basic and diluted 11,002,456 6,687,330 9,515,376 6,365,827 HTG Molecular Diagnostics, Inc. Condensed Consolidated Balance Sheets June 30, December 31, 2022 2021 Assets (Unaudited) Current assets: Cash and cash equivalents $ 5,756,578 $ 9,599,950 Short-term investments available-for-sale, at fair value 8,342,184 12,343,456 Accounts receivable, net 1,259,093 2,092,466 Inventory, net 1,955,922 1,987,753 Prepaid expenses and other 2,011,072 1,163,339 Total current assets 19,324,849 27,186,964 Operating lease right-of-use assets 1,143,270 1,345,361 Property and equipment, net 780,695 1,118,886 Other non-current assets 956,655 809,476 Total assets $ 22,205,469 $ 30,460,687 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,119,452 $ 1,649,440 Accrued liabilities 1,334,287 2,022,569 Current portion of long-term debt 6,614,817 5,167,586 NuvoGen obligation - current 523,849 548,301 Operating lease liabilities - current 429,200 413,865 Other current liabilities 137,644 141,749 Total current liabilities 10,159,249 9,943,510 NuvoGen obligation - non-current, net of discount 3,646,858 3,900,880 Long-term debt, net 2,023,579 5,178,629 Other non-current liabilities 806,094 1,037,844 Total liabilities 16,635,780 20,060,863 Commitments and Contingencies Total stockholders’ equity 5,569,689 10,399,824 Total liabilities and stockholders' equity $ 22,205,469 $ 30,460,687